Walking the path of treatable traits in interstitial lung diseases

被引:0
|
作者
Francesco Amati
Paolo Spagnolo
Christopher J. Ryerson
Justin M. Oldham
Andrea Gramegna
Anna Stainer
Marco Mantero
Nicola Sverzellati
Donato Lacedonia
Luca Richeldi
Francesco Blasi
Stefano Aliberti
机构
[1] Humanitas University,Department of Biomedical Sciences
[2] IRCCS Humanitas Research Hospital,Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health
[3] Respiratory Unit,Department of Medicine
[4] University of Padova,Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
[5] University of British Columbia and Centre for Heart Lung Innovation,Department of Pathophysiology and Transplantation
[6] St. Paul’s Hospital,Unit of Scienze Radiologiche, Department of Medicine and Surgery
[7] University of Michigan,Department of Medical and Occupational Sciences, Institute of Respiratory Disease
[8] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,undefined
[9] Respiratory Unit and Cystic Fibrosis Adult Center,undefined
[10] Università degli Studi di Milano,undefined
[11] University of Parma,undefined
[12] Università degli Studi di Foggia,undefined
[13] Fondazione Policlinico A. Gemelli IRCCS,undefined
[14] Università Cattolica del Sacro Cuore,undefined
来源
关键词
Treatable traits; Biomarkers; Endotype; Phenotype; Interstitial lung diseases; Personalized medicine; Artificial intelligence;
D O I
暂无
中图分类号
学科分类号
摘要
Interstitial lung diseases (ILDs) are complex and heterogeneous diseases. The use of traditional diagnostic classification in ILD can lead to suboptimal management, which is worsened by not considering the molecular pathways, biological complexity, and disease phenotypes. The identification of specific “treatable traits” in ILDs, which are clinically relevant and modifiable disease characteristics, may improve patient’s outcomes. Treatable traits in ILDs may be classified into four different domains (pulmonary, aetiological, comorbidities, and lifestyle), which will facilitate identification of related assessment tools, treatment options, and expected benefits. A multidisciplinary care team model is a potential way to implement a “treatable traits” strategy into clinical practice with the aim of improving patients’ outcomes. Multidisciplinary models of care, international registries, and the use of artificial intelligence may facilitate the implementation of the “treatable traits” approach into clinical practice. Prospective studies are needed to test potential therapies for a variety of treatable traits to further advance care of patients with ILD.
引用
收藏
相关论文
共 50 条
  • [1] Walking the path of treatable traits in interstitial lung diseases
    Amati, Francesco
    Spagnolo, Paolo
    Ryerson, Christopher J.
    Oldham, Justin M.
    Gramegna, Andrea
    Stainer, Anna
    Mantero, Marco
    Sverzellati, Nicola
    Lacedonia, Donato
    Richeldi, Luca
    Blasi, Francesco
    Aliberti, Stefano
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [2] Treatable traits in interstitial lung diseases: a call to action
    Amati, Francesco
    Spagnolo, Paolo
    Oldham, Justin M.
    Ryerson, Christopher J.
    Stainer, Anna
    Gramegna, Andrea
    Mantero, Marco
    Lacedonia, Donato
    Sverzellati, Nicola
    Richeldi, Luca
    Blasi, Francesco
    Aliberti, Stefano
    LANCET RESPIRATORY MEDICINE, 2023, 11 (02): : 125 - 128
  • [3] The prevalence of treatable traits in patients with fibrosing interstitial lung disease
    Lawler, C.
    Fermoyle, C.
    Troy, L.
    Glenn, L.
    Jee, A.
    Teoh, A.
    Jo, H.
    Jackson, D.
    Webster, S.
    Geis, M.
    He, T.
    Yuan, T.
    Harrison, M.
    Khor, Y.
    Corte, T.
    RESPIROLOGY, 2024, 29 : 218 - 218
  • [4] Reply: The concept and application of the treatable traits approach in interstitial lung disease and other chronic respiratory diseases
    Khor, Yet H.
    Ryerson, Christopher J.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (05)
  • [5] Treatable traits: a comprehensive precision medicine approach in interstitial lung disease
    Khor, Yet H.
    Cottin, Vincent
    Holland, Anne E.
    Inoue, Yoshikazu
    McDonald, Vanessa M.
    Oldham, Justin
    Renzoni, Elisabetta A.
    Russell, Anne Marie
    Strek, Mary E.
    Ryerson, Christopher J.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (01)
  • [6] Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies
    Wongkarnjana, Amornpun
    Scallan, Ciaran
    Kolb, Martin R. J.
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 436 - 442
  • [7] First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases
    Amati, Francesco
    Stainer, Anna
    Maruca, Giacomo
    De Santis, Maria
    Mangiameli, Giuseppe
    Torrisi, Chiara
    Bossi, Paola
    Polelli, Veronica
    Blasi, Francesco
    Selmi, Carlo
    Marulli, Giuseppe
    Balzarini, Luca
    Terracciano, Luigi Maria
    Gatti, Roberto
    Aliberti, Stefano
    BIOMEDICINES, 2024, 12 (05)
  • [8] Breathomics and treatable traits for chronic airway diseases
    Brinkman, Paul
    Maitland-van der Zee, Anke-Hilse
    Wagener, Ariane H.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (01) : 94 - 100
  • [9] The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic
    Simpson, Thomas
    West, Alex
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [10] Treatable traits in acute exacerbations of chronic airway diseases
    McDonald, Vanessa M.
    Osadnik, Christian R.
    Gibson, Peter G.
    CHRONIC RESPIRATORY DISEASE, 2019, 16